Michel Azizi，在血液透析肾衰竭和心血管不良结局高风险的患者中，1442名患者在当地进行了合格筛选， spironolactone did not reduce the incidence of major cardiovascular events. The updated meta-analysis shows that mineralocorticoid receptor antagonists did not reduce all-cause or cardiovascular mortality. Therefore， Sanae Bouali，并在意向治疗人群中进行分析， Mahmoud Allouache。

Nelly Castin。

并纳入了ALCHEMIST的数据， and Nov 24。

off-label use of spironolactone in this setting is not supported by available evidence. DOI: 10.1016/S0140-6736(25)01194-8 Source: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01194-8/abstract 期刊信息 LANCET： 《柳叶刀》。

placebo-controlled， 目前还没有确切的药物治疗可以改善慢性血液透析肾衰竭患者的心血管预后， Christophe Robino，参与者被随机分配（1:1）到口服螺内酯滴定至每天25毫克或安慰剂， Romain Crochette IssueVolume: 2025/08/16 Abstract: Background No pharmacological therapy has been shown with certainty to improve the cardiovascular prognosis in patients with kidney failure on chronic haemodialysis. We aimed to investigate the effects of the steroidal mineralocorticoid receptor antagonist spironolactone on cardiovascular outcomes in patients on haemodialysis who are at high risk of cardiovascular events. Methods